The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog ran from 2006 to 2016 and was intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Recent Posts

  • Recent Comments

    Insufficient proof of efficacy for marijuana spray to permit sale in the UK

    GW Pharmaceuticals was able to prove that Sativex, their marijuana oral spray product, was safe and reliably contained sufficient tetrahydrocannabinol. But proof of effectiveness was lacking, in the view of the UK’s Medicines and Healthcare products Regulatory Agency (MHRA)

    Sativex wasn’t being promoted to treat a specific symptom. Information from the company claims that clinical trials conducted in people with multiple sclerosis have shown promising results in the relief of spasticity, nerve pain, sleep disturbance, and bladder symptoms.

    Unfortunately, the scientific data were lacking.

    The bottom line?
    A study is being planned. Until then, UK doctors can order Sativex, although the process is more complicated than simply writing a prescription.

    Sativex is approved for use only in Canada.

    7/28/07 10:06 JR

    Leave a Comment

    You must be logged in to post a comment.